The next PARP M&A deal? Tesaro shares surge on latest buzz about a buyout
The PARP wars may be about ready to inspire some fresh M&A activity.
In the wake of Pfizer’s big $14 billion acquisition of Medivation last fall, which included the PARP drug talazoparib, sources are telling Reuters that Tesaro $TSRO has been fielding some incoming queries about a buyout. And with its PARP drug niraparib under review at the FDA, Tesaro has become one of the most frequently cited takeover targets in biotech, where promising late-stage assets can be hard to find.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.